Olomorasib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Olomorasib
- Molecular weight
- 528.97
- Structure (SMILES)
- C=CC(=O)N1CCN2C(=O)c3cc(F)c(-c4ccc(F)c5sc(N)c(C#N)c45)c(Cl)c3OCC[C@H]2C1
- ly 3537982
- LY-3537982
- ly3537982
- Ly3537982
- LY3537982
- olomorasib
- Olomorasib
- olomorasib [INN]
- OLOMORASIB [USAN]
- Olomorasib [WHO-DD]
- olomorasib inn
- olomorasib usan
- olomorasib who dd
- CAS registry numbers
- 2771246-13-8
- ChEMBL ID
- CHEMBL6068410
- InChIKey
- OZUPICRWMLEFCS-LBPRGKRZSA-N
- PubChem compound IDs
- 156472638
- FDA ingredient codes (UNII)
- C2VJ83PSN7
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- olomorasib
- Type
- Synthetic organic
- Drug name stem
- -rasib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- KRAS
- Gene symbol
- KRAS
- Protein identifier
- P01116
- Median affinity
- 9.02
- Affinity units
- pIC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
Trial references
- NCT06235983
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 99.66
- Calculated partition coefficient (ALogP)
- 4.58
- Calculated partition coefficient (XLogP)
- 4.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 36
- Molecular formula
- C25H19ClF2N4O3S
- Monoisotopic mass
- 528.0834457
- Natural product
- No
- Recorded assays
- 56
- Active assays
- 3
Active assay types
- Confirmatory
Related records
Trials (15)
- A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
- A Study of [14C]-LY3537982 in Healthy Participants
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
- A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
- A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
- A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
- A Study of Olomorasib (LY3537982) in Healthy Participants
- A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
- A Study of the Effect of Food on LY3537982 in Healthy Participants
- A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
- Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
In development for (1)
- Neoplasm Phase 1